Actuate Therapeutics, Inc. ACTU
Actuate Therapeutics, Inc. (Nasdaq: ACTU) is an oncology drug developer. Its lead program, elraglusib (IV injection), is in Phase 2 for first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). Its next catalyst on record is Elraglusib Injection (BEACON2): Planned University of Birmingham BEACON2 neuroblastoma dose-confirmation cohort (up to 20 patients) (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Elraglusib Injection (BEACON2) — Planned University of Birmingham BEACON2 neuroblastoma dose-confirmation cohort (up to 20 patients) (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Elraglusib Injection (Actuate-1801 Part 3B) | first-line mPDAC | small molecule | Phase 2 |
| Elraglusib Injection (Actuate-1902) | pediatric relapsed/refractory solid tumors (Ewing sarcoma, neuroblastoma) | small molecule | Phase 1 |
| Elraglusib Oral Tablet | advanced refractory cancers | small molecule | Pre-clinical |
Recent results and decisions
- May 11, 2026met Randomized Phase 2 met primary endpoint: elraglusib + GnP improved median OS 10.1 vs 7.2 months (HR 0.62, p=0.02) and doubled 1-year OS (44.4% vs 22.3%, p=0.0004).
Elraglusib + GnP doubled 1 - year OS vs. GnP alone (p=0.0004)
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.